The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial*

Youssef, JG; Lavin, P; Schoenfeld, DA; Lee, RA; Lenhardt, R; Park, DJ; Fernandez, JP; Morganroth, ML; Javitt, JC; Jayaweera, D

Youssef, JG (通讯作者)，Houston Methodist Hosp, Houston Methodist Pulm Transplant Ctr, Houston, TX 77030 USA.;Youssef, JG (通讯作者)，Houston Methodist Hosp, Dept Acad Pulmonol, Houston, TX 77030 USA.

CRITICAL CARE MEDICINE, 2022; 50 (11): 1545

Abstract

OBJECTIVES: Respiratory failure is a lethal complication of COVID-19 that has remained resistant to drug therapy. Vasoactive intestinal peptide (VIP) ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索